Matches in Wikidata for { <http://www.wikidata.org/entity/Q94153932> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q94153932 description "article scientifique publié en 2018" @default.
- Q94153932 description "wetenschappelijk artikel" @default.
- Q94153932 description "наукова стаття" @default.
- Q94153932 name "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 name "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 type Item @default.
- Q94153932 label "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 label "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 prefLabel "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 prefLabel "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 P1433 Q94153932-8478F79C-D002-4A0B-AF5F-773D4618F844 @default.
- Q94153932 P1476 Q94153932-512AEE26-1A55-4574-B4D2-883DC96C8CEC @default.
- Q94153932 P2093 Q94153932-03430EE0-816B-4713-9048-4CFB3061A364 @default.
- Q94153932 P2093 Q94153932-0498ECAC-85D1-4981-B040-82945198D8C0 @default.
- Q94153932 P2093 Q94153932-47D15339-E86A-4BF1-A9AC-71CB3D403495 @default.
- Q94153932 P2093 Q94153932-7D6FCC87-A8FE-4505-A9A2-21C0E5045DBE @default.
- Q94153932 P2093 Q94153932-EA373C77-135B-4B1F-BAE6-E48C5AC58343 @default.
- Q94153932 P2093 Q94153932-EB010D23-0E48-40A7-B3F1-D8474BB8729E @default.
- Q94153932 P304 Q94153932-B03BD694-20B1-4352-8C4D-ADF142F26D96 @default.
- Q94153932 P31 Q94153932-E57AF3F0-D1F4-4CD6-B025-E2D681E264CD @default.
- Q94153932 P356 Q94153932-2E6EE512-7B7D-4181-95C8-4449F96C6289 @default.
- Q94153932 P433 Q94153932-FDD404A1-CE24-4138-90DD-48688618039D @default.
- Q94153932 P478 Q94153932-CA0647D5-2B71-43AD-80D3-FD919F94FA8F @default.
- Q94153932 P50 Q94153932-B0AC6B20-CE82-40E7-925D-165A679EFADC @default.
- Q94153932 P577 Q94153932-D6E90996-B0DB-49C8-81A4-F61A77896AF6 @default.
- Q94153932 P921 Q94153932-F734B458-3731-4113-BDD4-FF2024D6C160 @default.
- Q94153932 P921 Q94153932-FEDBB494-1FBC-4941-AEA8-FCF69909E3A4 @default.
- Q94153932 P932 Q94153932-A593F635-2A21-462C-BDA3-9527ABB00956 @default.
- Q94153932 P356 NOY148.971 @default.
- Q94153932 P1433 Q15724471 @default.
- Q94153932 P1476 "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA" @default.
- Q94153932 P2093 "Cathy Schilero" @default.
- Q94153932 P2093 "David Peereboom" @default.
- Q94153932 P2093 "David Reardon" @default.
- Q94153932 P2093 "Deborah Forst" @default.
- Q94153932 P2093 "Eric Wong" @default.
- Q94153932 P2093 "Manmeet Ahluwalia" @default.
- Q94153932 P304 "vi234-vi234" @default.
- Q94153932 P31 Q13442814 @default.
- Q94153932 P356 "10.1093/NEUONC/NOY148.971" @default.
- Q94153932 P433 "Suppl 6" @default.
- Q94153932 P478 "20" @default.
- Q94153932 P50 Q105531697 @default.
- Q94153932 P577 "2018-11-05T00:00:00Z" @default.
- Q94153932 P921 Q282142 @default.
- Q94153932 P921 Q413299 @default.
- Q94153932 P932 "6217628" @default.